Indegene Ltd

Indegene Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Indegene Ltd

₹ 640 -0.09%
22 Nov - close price
indegene.com BSE: 544172 NSE: INDGN
About

It is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way.

Key Points

Business Divison[1]
A) Enterprise Commercial Solutions aids life science companies in optimizing digital marketing operations, driving scale efficiency, and implementing technology-enabled personalization strategies for engagement with HCPs, patients, and operations.

Website BSE NSE
  • Market Cap ₹ 15,320 Cr.
  • Current Price ₹ 640
  • High / Low ₹ 737 / 469
  • Stock P/E 98.3
  • Book Value ₹ 74.1
  • Dividend Yield 0.00 %
  • ROCE 18.4 %
  • ROE 14.2 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 18.9%

Cons

  • Stock is trading at 8.64 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Earnings include an other income of Rs.71.2 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Healthcare Industry: Miscellaneous

Part of Nifty 500 Multicap 50:25:25 BSE Allcap BSE Healthcare Nifty Smallcap 250 Nifty Total Market

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
256 252 260 260 272 259 282
212 215 217 223 226 219 235
Operating Profit 44 38 43 37 46 40 46
OPM % 17% 15% 17% 14% 17% 15% 16%
9 12 6 12 23 14 22
Interest 2 2 2 2 2 2 2
Depreciation 10 9 8 6 8 7 6
Profit before tax 42 39 39 41 60 45 61
Tax % 32% 24% 26% 27% 19% 28% 27%
28 30 29 30 49 33 45
EPS in Rs 1.28 1.33 1.32 1.33 2.20 1.36 1.87
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
282 334 511 837 1,006 1,046 1,073
230 249 361 668 828 878 904
Operating Profit 53 86 150 169 178 168 169
OPM % 19% 26% 29% 20% 18% 16% 16%
12 -24 30 28 37 50 71
Interest 1 3 4 3 6 7 6
Depreciation 4 13 18 24 32 31 27
Profit before tax 59 46 159 170 177 181 207
Tax % 14% 30% 17% 22% 26% 24%
51 32 132 133 130 138 156
EPS in Rs 324.22 202.30 843.58 755.26 5.87 6.20 6.76
Dividend Payout % 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 30%
3 Years: 27%
TTM: 4%
Compounded Profit Growth
10 Years: %
5 Years: 20%
3 Years: -1%
TTM: -4%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: 26%
3 Years: 19%
Last Year: 14%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 0.31 0.30 0.30 0.40 44 44 48
Reserves 158 -3 254 650 751 909 1,726
106 362 23 44 51 38 32
57 72 96 156 191 228 240
Total Liabilities 322 431 373 850 1,038 1,220 2,046
8 31 41 72 78 56 47
CWIP 0 0 0 0 0 0 0
Investments 134 251 83 203 400 624 784
180 148 249 575 559 540 1,215
Total Assets 322 431 373 850 1,038 1,220 2,046

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
62 90 53 38 82 176
-70 -51 -34 -267 -51 -189
15 -18 -37 245 -17 -16
Net Cash Flow 8 20 -18 16 14 -29

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 65 65 125 152 145 132
Inventory Days
Days Payable
Cash Conversion Cycle 65 65 125 152 145 132
Working Capital Days 51 21 84 107 118 109
ROCE % 28% 49% 36% 24% 18%

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2024Sep 2024
3.79% 4.82%
3.84% 3.17%
92.38% 92.01%
No. of Shareholders 2,03,5991,51,440

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Concalls